Professor Ravindra Gupta is an AHRI faculty member and a professor of clinical microbiology at the Cambridge Institute for Therapeutic Immunology and Infectious Diseases. In 2020, Ravi was named as one of TIME’s 100 most influential people of 2020.
Ravi initially trained as a clinical infectious diseases physician and went on to do a PhD at University College London, where he examined the epidemiology and virology of HIV drug resistance in sub-Saharan Africa and the interplay between the restriction factor tetherin and the HIV gene Vpu. Most of his work since has focussed on antiviral therapy for treatment of HIV, and he has led a number of studies, both clinical and in vitro, aimed at addressing the global emerging threat of drug resistant HIV. His programme of work is informed by clinical work as an infectious diseases physician, through which he has been able to study unique individuals with HIV in order to better understand viral reservoirs and immune control of HIV.
Get in touch with Ravi via firstname.lastname@example.org
Click here for a full list of publications.
The Gupta Group has teams at both Africa Health Research Institute in South Africa, and at the University of Cambridge in the UK. Prof Ravi Gupta has had continuous Wellcome funding as a Fellow since 2007, and most recently secured a Wellcome Senior Fellowship in 2016 to study the biological properties of drug resistant viruses in South Africa, including acquisition of increased replication fitness and cellular tropism changes as part of evolutionary adaptation to drug pressure. Africa Health Research Institute represents an ideal environment in which to study drug resistant HIV-1, given the large numbers of treated patients and the fact that 10% or more patients experience treatment failure. This project brings together the multiple strands of his ongoing research to address critically important consequences of global access to antiretroviral therapy. Future plans include work on the role of myeloid cells in HIV associated brain disease during antiretroviral therapy, paving the way to study drug resistant reservoirs in the brain.
Meet the Team
Collaborating Research Fellow
Dami is a physician specialising in Infectious Diseases and a Wellcome Clinical PhD student at University College London. At AHRI Dami facilitates the HERB (HIV escape and resistance in the brain) study, which aims to investigate the occurrence of independent replication of HIV in the brain of South African patients with neurocognitive impairment and to study the evolution of drug resistance in these compartmentalised viruses.
Selected Recent Publications
Meng, Bo, et al . Altered TMPRSS2 Usage by SARS-CoV-2 Omicron Impacts Infectivity and Fusogenicity. Nature, vol. 603, no. 7902, Mar. 2022, pp. 706–14.
Mlcochova, Petra, et al. SARS-CoV-2 B.1.617.2 Delta Variant Replication and Immune Evasion. Nature, vol. 599, no. 7883, Nov. 2021, pp. 114–19.
Collier, Dami A., et al. Age-Related Immune Response Heterogeneity to SARS-CoV-2 Vaccine BNT162b2. Nature, vol. 596, no. 7872, Aug. 2021, pp. 417–22.
The CITIID-NIHR BioResource COVID-19 Collaboration, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to MRNA Vaccine-Elicited Antibodies. Nature, vol. 593, no. 7857, May 2021, pp. 136–41.
The CITIID-NIHR BioResource COVID-19 Collaboration, et al. SARS-CoV-2 Evolution during Treatment of Chronic Infection. Nature, vol. 592, no. 7853, Apr. 2021, pp. 277–82.
Siedner, Mark J., et al. Reduced Efficacy of HIV-1 Integrase Inhibitors in Patients with Drug Resistance Mutations in Reverse Transcriptase. Nature Communications, vol. 11, no. 1, Dec. 2020, p. 5922.
Gupta-Wright, Ankur, et al. Virological Failure, HIV-1 Drug Resistance, and Early Mortality in Adults Admitted to Hospital in Malawi: An Observational Cohort Study. The Lancet HIV, vol. 7, no. 9, Sept. 2020, pp. e620–28.
Datir, Rawlings, et al. In Vivo Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix. MBio, edited by Dimitrios Paraskevis, vol. 11, no. 6, Dec. 2020, pp. e02036-20.
Mlcochova P, Sutherland KA, Watters SA, Bertoli C, de Bruin RAM, Rehwinkel J, Neil SJ, Lenzi GM, Kim B, Khwaja A, Gage MC, Georgiou C, Chittka A, Yona S, Noursadeghi M, Towers GJ, Gupta RK. (2017). A G1–like state allows HIV–1 to bypass SAMHD1 restriction in macrophages. EMBO J 2017; Mar 1;36(5):604-616.
Collier DA, Iwuji C, Derache A, de Oliveira T, Okesola N, Calmy A, Dabis F, Pillay D, Gupta RK for the ANRS 12249 TasP Study Group. (2017). Virological Outcomes of second–line protease inhibitor based treatment for HIV– 1 in a high prevalence rural South African setting – a competing risk prospective cohort analysis. Clinical Infectious Diseases; doi: 10.1093/cid/cix015; E pub ahead of print.
Sutherland KA, Collier DA, Claiborne DT, Prince JL, Deymier MJ, Goldstein RA, Hunter E, Gupta RK. (2016). Wide variation in susceptibility of HIV–1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency. Scientific Reports; 6: 38153 doi: 10.1038/srep38153 .
Gregson J, Kaleebu P, Marconi VC, van Vuuren C, Ndembi N, Hamers RL, Kanki P, Hoffmann CJ, Lockman S, Pillay D, de Oliveira T, Clumeck N, Hunt G, Kerschberger B, Shafer RW, Yang C, Raizes E, Kantor R, Gupta RK. (2017). Occult drug resistance to thymidine analogues and multidrug resistant HIV–1 following failure of first line tenofovir–based antiretroviral regimens in sub Saharan Africa: a retrospective multi–centre cohort study. Lancet Infect Dis Epub ahead of print: http://dx.doi.org/10.1016/S1473– 3099(16)30469– 8.
Gregson J, Tang M, Ndembi N, Hamers RL, Rhee SY, Marconi VC, Diero L, Brooks K, Theys, K, Rinke de Wit TF, Arruda M, Garcia F, Monge S, Günthard, HF, Hoffmann, CJ, Kanki PJ, Kumarasamy, N, Kerschberger B, Mor O, Charpentier C, Todesco E, Rokx C, Gras L, Halvas EK, Sunpath H, Di Carlo D, Antinori A, Andreoni M, Latini A, Mussini C, Aghokeng A, Sonnerborg A, Ujjwal Neogi U, Fessel WJ, Agolory S, Yang C, Blanco JL, Juma JM, Smit, E, Schmidt, D, Watera C, Asio J, Kirungi W, Tostevin A, El– Hay T, Clumeck N, Goedhals D; van Vuuren C, Bester PA, Sabin C, Mukui I, Santoro MM, Perno CF, Hunt G, Morris L, Camacho R, de Oliveira T, Pillay D, Schulter E, Akio Murakami– Ogasawara A, Reyes– Terán G, Romero K, Avila– Rios S, Sirivichayakul, S, Ruxrungtham K, Mekprasan S, Dunn, D, Kaleebu, P, Raizes E, Kantor R, Shafer RW, Gupta RK on behalf of the TenoRes study group. (2016). Global epidemiology of drug resistance following failure of WHO recommended first line regimens for adult HIV–1 infection – a multi–centre retrospective cohort study. Lancet Infect Dis 2016. May;16(5):565– 75.